Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Sinovac Files to Start Clinical Trial of Infant Pneumococcal Vaccine

publication date: Mar 3, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinovac Biotech has filed an application with the SFDA to begin clinical trials of its 13-valent pneumococcal conjugate vaccine (PCV). The target market for the vaccine is infants under the age of two, a population that currently numbers 34 million in China. Sinovac also anticipates participating in a United Nations program that supplies PCV to developing nations. More details....

Stock Symbol: (NSDQ: SVA)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...